Lipocalin-2

Circulating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

BACKGROUND

Cancer-associated anorexia (AN) and cachexia are frequent and debilitating complications of cancer, driven by systemic inflammation and metabolic dysregulation. Lipocalin 2 (LCN2) has been implicated in immune-metabolic integration and central appetite control, however data in cancer patients are limited. This...

🗓️ 2026-11-03
📰 Publication: Frontiers In Nutrition
Read MoreCirculating lipocalin-2 is associated with systemic inflammation and cachexia-related features in patients with gastrointestinal cancer.

Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

A bidirectional relationship exists between metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), and sarcopenia, with each worsening the prevalence and prognosis of the other. Hepatokines have recently been shown to affect skeletal...

🗓️ 2026-06-11
📰 Publication: Molecular Metabolism
Read MoreHepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!